Policy

Invex Therapeutics (ASX:IXC) has announced encouraging new findings from its research collaboration with Tessara Therapeutics, showing additional neuroprotective benefits of exenatide in a laboratory model of Alzheimer’s disease.

A new clinical trial now underway in New South Wales and Queensland is offering hope to the approximately 260,000 Australians living with vitiligo. This autoimmune skin condition can have a profound impact on mental health and well-being.

Chairman and CEO Mick Farrell said the results underscored the company’s ongoing transformation of home healthcare through a combination of hardware, software, and digital innovation.

Regenerative medicine company Orthocell (ASX OCC) has marked another significant milestone in its global expansion, completing the first surgical case using its flagship nerve repair device, Remplir, in Hong Kong.

Actinogen Medical (ASX:ACW) is showcasing its lead therapy, XANAMEM (emestedastat), and the company’s advancing clinical program for Alzheimer’s disease and depression this week at BIO-Europe 2025, Europe’s largest biotechnology partnering conference.

Anteris Technologies (ASX:AVR) has received U.S. Food and Drug Administration approval to begin its global pivotal PARADIGM Trial, a randomised study evaluating the company’s DurAV Transcatheter Heart Valve for patients with severe calcific aortic stenosis.

Aroa Biosurgery (ASX: ARX) has announced the appointment of Paul Shearer as a Non-Executive Director, effective immediately, following the retirement of long-serving Director John Pinion after a decade of service.

Firebrick Pharma (ASX:FRE) has expanded its Nasodine product range, announcing the manufacture of Nasodine Throat Spray, its first new product since the successful launch of Nasodine Nasal Spray in Singapore in 2024.

Immuron (ASX:IMC) has provided an update on its U.S. clinical programs for Travelan and IMM-529, confirming progress in its regulatory engagement with the U.S. Food and Drug Administration and outlining next steps following minor protocol updates.

Amplia Therapeutics (ASX:ATX) has commenced trading on the U.S. OTCQB Venture Market under the ticker INNMF, expanding access for U.S. investors to the company’s common stock.

The latest issue of the Australasian Journal of Biotechnology (Volume 35, Number 2) is now available, showcasing the people and ideas shaping Australia’s life sciences future.

One of Australia’s most influential philanthropic institutions, the Sylvia and Charles Viertel Charitable Foundation, is celebrating 30 years of supporting local health and medical research with more than $90 million invested and a legacy of breakthroughs now shaping clinical care around the world.